🐯虎嗅•Stalecollected in 63m
Shanghai's New Policy for Original Drug Payments
#healthcare-policy#pharmaceuticals#market-accessshanghai-medical-insurance-policyshanghai-healthcare-bureau
💡Understand how policy shifts in drug pricing create new data-driven opportunities for pharmaceutical market analysis.
⚡ 30-Second TL;DR
What Changed
The new policy allows patients to choose original drugs by paying the difference between the drug price and the centralized procurement reimbursement cap.
Why It Matters
This policy signals a shift in healthcare management towards market-based competition for high-value drugs, potentially impacting pharmaceutical R&D investment strategies in China.
What To Do Next
Analyze the impact of this policy on pharmaceutical data analytics—specifically how real-world evidence (RWE) can now be used to justify the price premium of original drugs.
Who should care:Enterprise & Security Teams
Key Points
- •The new policy allows patients to choose original drugs by paying the difference between the drug price and the centralized procurement reimbursement cap.
- •It removes the strict procurement ratio constraints for non-selected drugs in community health centers.
- •This policy creates a market space for original drugs and potentially encourages the growth of commercial health insurance.
🧠 Deep Insight
Web-grounded analysis with 18 cited sources.
🔑 Enhanced Key Takeaways
- •Shanghai's new policy, effective May 1, 2026, specifically transitions from percentage-based to fixed-amount reimbursements for hundreds of drugs from the 11th national volume-based procurement (VBP) batch.
- •This fixed-amount reimbursement model adopted by Shanghai is the first of its kind in China and is anticipated to serve as a precedent for similar policy changes across the nation.
- •The policy aligns with a broader national strategy to foster commercial health insurance as a supplementary system to basic medical insurance, particularly for innovative and high-cost drugs that are not covered by the National Reimbursement Drug List (NRDL).
- •On April 14, 2026, China's State Council issued a policy to reform the drug pricing system, shifting towards a more market-driven approach for innovative medicines and granting pharmaceutical companies greater flexibility in setting initial prices for newly launched drugs.
- •The National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security jointly released China's first-ever Commercial Health Insurance Innovative Drug List (CHIIDL) on December 7, 2025, which became effective January 1, 2026, to cover highly innovative drugs with significant clinical value that are typically excluded from the NRDL.
🔮 Future ImplicationsAI analysis grounded in cited sources
Increased market access for innovative and original drugs in China.
Shanghai's pilot, coupled with national encouragement for commercial insurance and market-driven pricing, creates new avenues for high-value drugs outside strict VBP price cuts.
Accelerated growth and diversification of China's commercial health insurance market.
Explicit government support and the introduction of lists like CHIIDL incentivize commercial insurers to offer coverage for innovative drugs, thereby filling gaps in basic medical insurance.
Establishment of a more robust multi-tiered healthcare payment system in China.
The policy differentiates between basic coverage (VBP) and patient choice for original drugs (fixed-amount reimbursement, commercial insurance), leading to a more stratified system that caters to diverse patient needs and drug types.
⏳ Timeline
2009
China initiated health reforms, including the Zero Markup Drug Policy (ZMDP), to eliminate economic incentives for overprescribing in public hospitals.
2018
China launched the pilot National Volume-Based Procurement (VBP) program in 11 cities, known as the '4+7' pilot.
2019
The National VBP policy was implemented nationwide, significantly expanding its scope.
2025-01-01
The 2024 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue became effective.
2025-12-07
The National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security released the first-ever Commercial Health Insurance Innovative Drug List (CHIIDL).
2026-04-14
China's State Council issued opinions on the formation mechanism of drug prices, promoting diversified payment for innovative drugs and market-driven pricing.
2026-05-01
Shanghai implemented its new policy for fixed-amount reimbursement for original drugs not selected in national centralized procurement.
📎 Sources (18)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗